Is Evolus, Inc. overvalued or undervalued?

As of 12 August 2019, the valuation grade for Evolus, Inc. has moved from does not qualify to risky, indicating a significant concern regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of -98.02 and an EV to EBITDA ratio of -23.65. Additionally, the Return on Capital Employed (ROCE) stands at a troubling -72.79%, further highlighting the company's struggles.
In comparison to its peers, Evolus, Inc. has a P/E ratio of -12.3086, which is less favorable than Tarsus Pharmaceuticals, Inc. at -16.0798 and Travere Therapeutics, Inc. at -5.5910. These ratios suggest that Evolus is not only underperforming relative to its peers but also reflects a broader trend of negative valuations within the sector. The company's stock has underperformed against the S&P 500 over various time frames, including a year-to-date decline of 15.04% compared to a 2.44% gain in the index, reinforcing the notion that Evolus is currently overvalued.